Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

13.0%

6 terminated/withdrawn out of 46 trials

Success Rate

87.0%

+0.5% vs industry average

Late-Stage Pipeline

11%

5 trials in Phase 3/4

Results Transparency

18%

7 of 40 completed trials have results

Key Signals

7 with results6 withdrawn

Enrollment Performance

Analytics

Phase 1
35(77.8%)
Phase 3
5(11.1%)
Phase 2
3(6.7%)
N/A
1(2.2%)
Early Phase 1
1(2.2%)
45Total
Phase 1(35)
Phase 3(5)
Phase 2(3)
N/A(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (46)

Showing 20 of 46 trials
NCT05041699Phase 1Completed

PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel

Role: lead

NCT05416021Phase 1Completed

Relative Bioavailability Trial of Dapivirine Ring-004 and Ring-008

Role: lead

NCT01617096Phase 3Completed

Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women

Role: lead

NCT02010593Phase 2Completed

Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women

Role: lead

NCT02862171Phase 3Completed

To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women

Role: lead

NCT00799058Phase 1Completed

A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States

Role: lead

NCT02858037Phase 3Completed

Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women

Role: lead

NCT02028338Phase 2Completed

Study of Dapivirine Vaginal Ring (VR) in Adolescents

Role: lead

NCT01539226Not ApplicableCompleted

Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women

Role: lead

NCT03467347Phase 1Completed

PK Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel

Role: lead

NCT01618058Completed

Observational Study of HIV Infection in Participants of Seroconvert During Dapivirine Vaginal Ring Trials

Role: lead

NCT03234400Phase 1Completed

A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings

Role: lead

NCT02855346Phase 1Completed

PK and Safety Study of Vaginal Rings Containing Dapivirine and Levonorgestrel

Role: lead

NCT01755741Phase 1Completed

Functionality of Male Condoms With a Silicone Elastomer Vaginal RIng

Role: lead

NCT02808949Phase 1Completed

Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women

Role: lead

NCT01755754Phase 1Completed

A Trial to Assess the Functionality of Female Condom With a Silicone Elastomer Vaginal Ring

Role: lead

NCT01731574Phase 1Completed

DDI Potential: Dapivirine Vaginal Ring and Miconazole Nitrate

Role: lead

NCT02920827Phase 1Completed

Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Vaginal Ring

Role: lead

NCT02346084Phase 1Completed

Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults

Role: lead

NCT01548560Phase 1Completed

Assessing the Safety of Dapivirine Gel and Film Formulations

Role: lead